Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form 4

INTRABIOTICS PHARMACEUTICALS INC /DE

Form 4

December 27, 2006

Section 16.

Form 4 or

FORM 4		OMB AP	PROVAL
1 OI IIVI 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549	OMB Number:	3235-028
Check this box if no longer	g ,	Expires:	January 3
subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF	Estimated a	verage

SECURITIES

Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Baker / Tisch Capital (GP), LLC			2. Issuer Name and Ticker or Trading Symbol INTRABIOTICS PHARMACEUTICALS INC /DE [IBPI]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner		
(Last) 667 MADISO	(First) N AVENUE	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 12/22/2006	Officer (give title below) Other (specify below)		
NEW YORK,	(Street) NY US 1002	21	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person		

(City)	(State)	(Zip)	Table I - I	Non-Derivative Securities Ac	quired, Disposed	of, or B	enefic	ially Owned			
1.Title of	2. Transaction Date	2A. Deemed	3.	4. Securities Acquired	5. Amount of	6.		7. Nature of			

Security	(Month/Day/Year)	Execution Date, if	Transactio	or(A) or D	ispose	ed of (D)	Securities	Ownership	Indirect
(Instr. 3)		any	Code	(Instr. 3,	4 and	5)	Beneficially	Form:	Beneficial
		(Month/Day/Year)	(Instr. 8) Code V	Amount	(A) or (D)	Price	Owned Following Reported Transaction(s) (Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock (1) (2)	12/22/2006		P	2,904	A	\$ 3.8511	11,058 (3)	I	Through Partnership (4)
Common Stock (1) (2)	12/26/2006		P	1,558	A	\$ 4	12,616 (3)	I	Through Partnership (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form

3235-0287

January 31,

burden hours per

response...

2005

0.5

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)		4.	5. onNumber	6. Date Exerc Expiration D		7. Tit	le and	8. Price of Derivative	9. Nu Deriv
Security (Instr. 3)	or Exercise Price of Derivative Security	(Month/Day/Teat)	any (Month/Day/Year)	Code (Instr. 8)	of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3,	(Month/Day/ e		Unde	rlying	Security (Instr. 5)	Secur Bene Owne Follo Repo Trans (Instr
				Code V	4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Baker / Tisch Capital (GP), LLC 667 MADISON AVENUE 17TH FLOOR NEW YORK, NY US 10021		X				
BAKER JULIAN 667 MADISON AVENUE, 17TH FLOOR NEW YORK, NY US 10021		X				
BAKER FELIX 667 MADISON AVENUE, 17TH FLOOR NEW YORK, NY US 10021		X				

Signatures

/s/ Julian C. Baker, as M	Managing Member of Baker/ Tisch Capital (GP),	
LLC	1 , , ,	12/27/2006
	**Signature of Reporting Person	Date
/s/ Julian C. Baker		
75/ Julian C. Dakei		12/27/2006
	**Signature of Reporting Person	Date
/s/ Felix J. Baker		
78/ Pelix J. Dakei		12/27/2006
	**Signature of Reporting Person	Date

Reporting Owners 2

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- In addition to Baker/ Tisch Capital (GP), LLC, this Form 4 is being filed jointly by Julian C. Baker and Felix J. Baker, each of whom has the same business address as Baker/ Tisch Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it.

 Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational
- purposes as if they were a member of a group of such shareholders. (Continued in footnote 2).
- However, the Reporting Persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.
- Includes dividends paid in shares of common stock on September 27, 2005, May 25, 2006, August 8, 2006, and October 25, 2006 to all holders of Series A preferred stock, as a result of which Baker/Tisch Investments, L.P., received 455 shares, 458 shares, 450 shares, and 414 shares of common stock, respectively.
- Represents securities owned directly by Baker/ Tisch Investments, L.P., the sole general partner of which is Baker/ Tisch Capital, L.P., a

 (4) limited partnership the sole general partner of which is Baker/ Tisch Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker/ Tisch Capital (GP), LLC.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.